110 related articles for article (PubMed ID: 19438554)
1. Perilesional treatment of metastatic melanoma with interferon-beta.
Fujimura T; Okuyama R; Ohtani T; Ito Y; Haga T; Hashimoto A; Aiba S
Clin Exp Dermatol; 2009 Oct; 34(7):793-9. PubMed ID: 19438554
[TBL] [Abstract][Full Text] [Related]
2. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
[TBL] [Abstract][Full Text] [Related]
3. Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon.
Nakayama J; Takeuchi M; Mayumi H; Nagae S; Matsuda K; Yasui H; Takahashi S; Hori Y
J Dermatol; 1996 Jan; 23(1):6-15. PubMed ID: 8720252
[TBL] [Abstract][Full Text] [Related]
4. Intralesional therapy of metastatic spreading melanoma with beta-interferon.
Rapprich H; Hagedorn M
J Dtsch Dermatol Ges; 2006 Sep; 4(9):743-6. PubMed ID: 16928243
[TBL] [Abstract][Full Text] [Related]
5. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
Konjević G; Jović V; Radomirović V; Spuzić I
Glas Srp Akad Nauka Med; 2002; (47):121-36. PubMed ID: 16078447
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.
Piras F; Colombari R; Minerba L; Murtas D; Floris C; Maxia C; Corbu A; Perra MT; Sirigu P
Cancer; 2005 Sep; 104(6):1246-54. PubMed ID: 16078259
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
9. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
[TBL] [Abstract][Full Text] [Related]
10. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.
Carlsson B; Sadeghi A; Bengtsson M; Wagenius G; Tötterman TH
J Immunother; 2008 Sep; 31(7):633-43. PubMed ID: 18600181
[TBL] [Abstract][Full Text] [Related]
11. [Intralesional therapy of melanoma metastases with recombinant interferon-beta].
Fierlbeck G; d'Hoedt B; Stroebel W; Stutte H; Bogenschütz O; Rassner G
Hautarzt; 1992 Jan; 43(1):16-21. PubMed ID: 1612904
[TBL] [Abstract][Full Text] [Related]
12. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.
Nasi ML; Lieberman P; Busam KJ; Prieto V; Panageas KS; Lewis JJ; Houghton AN; Chapman PB
Cytokines Cell Mol Ther; 1999 Sep; 5(3):139-44. PubMed ID: 10641571
[TBL] [Abstract][Full Text] [Related]
13. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
[TBL] [Abstract][Full Text] [Related]
14. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional beta-interferon injection.
Paul E; Müller I; Renner H; Bödeker RH; Cochran AJ
Melanoma Res; 2003 Dec; 13(6):611-7. PubMed ID: 14646625
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells.
Kubo H; Ashida A; Matsumoto K; Kageshita T; Yamamoto A; Saida T
Arch Dermatol Res; 2008 Jul; 300(6):297-301. PubMed ID: 18324409
[TBL] [Abstract][Full Text] [Related]
16. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V alpha specificities present in T-cells of normal human skin.
Strohal R; Paucz L; Pehamberger H; Stingl G
Cancer Res; 1994 Sep; 54(17):4734-9. PubMed ID: 8062272
[TBL] [Abstract][Full Text] [Related]
18. Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.
Zennadi R; Abdel-Wahab Z; Seigler HF; Darrow TL
Cell Immunol; 2001 Jun; 210(2):96-105. PubMed ID: 11520076
[TBL] [Abstract][Full Text] [Related]
19. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM
Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051
[TBL] [Abstract][Full Text] [Related]
20. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]